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REPORTS
ORAL METHOXSALEN PHOTOCHEMOTHERAPY FOR THE TREATMENT OF
PSORIASIS: A COOPERATIVE CLINICAL TRIAL
JOHN W. MELSKI, M.D., LEWIS TANENBAUM, M.D., JOHN A. PARRISH, M.D., THOMAS B. FITZPATRICK, M.D.,
HOWARD L. BLEICH, M.D., AND 28 PARTICIPATING INVESTIGATORS*
Extensive psoriasis in 1,308 patients has been treated two or three times a week with oral 8-methoxypsoralen
followed by high intensity, long-wave ultraviolet light (PUVA). Excluding 169 patients still under early treatment,
psoriasis cleared in 88% and failed to clear in 3%. One percent dropped out due to complications of treatment,
and 8% for other reasons. The twice-a-week schedule was superior for patients with lighter skin types. Once a
remission was induced, there was no difference in its maintenance when patients were treated once a week,
once every other week, or once every third week. Each of these schedules was superior to no maintenance
treatment. Immediate side effects of the 45,000 treatments administered in the first 18 months of this study were
uncommon, temporary, and generally mild. No clinically significant changes in laboratory screening or eye
examinations attributable to PUVA have been uncovered.
In December, 1974, the first report was published on the
use of oral 8-methoxypsoralen followed by high-intensity,
long-wave ultraviolet light (UVA, 320 nm) for the treat-
ment of psoriasis [I]. The treatment is known as PUVA
(psoralen plus UVA). In July, 1975, a randomized
cooperative clinical trial was initiated among 16 centers
in the United States to investigate the safety and efficacy of
various PUVA treatment schedules. This report is based on
data obtained by the participating investigators on 45,000
treatments administered to 1,308 patients during the first
18 months of this ongoing study. (The participating
investigators, the centers, and the number of patients
from each center are listed in Appendix 1.)
PUVA is an experimental technique, not yet approved
by the Food and Drug Administration, that has been used
to induce and maintain a temporary remission of psoriasis.
In the present study, each of the 16 centers was asked to
enter 50 or more patients with at least 30% of their body
affected by psoriasis at the time of the first treatment. After
50 such patients were entered, patients with less involve-
ment could be included. Exclusions for entry were
pregnancy, aphakia, use of systemic cytotoxic agents
within a month of the first treatment, and use of topical
medications other than emollients for areas other than the
scalp, intertriginous regions, or soles of feet.
METHODS
8-Methoxypsoralen was provided in 10-mg capsules and
administered according to the schedule in Appendix 2. Special
UVA light box treatment systems developed and prepared by the
GTE Sylvania Lighting Products Group, Danvers, Mass, were
used [12]. UVA treatments were given 2 to 3 h after ingestion of
8-methoxypsoralen (Oxsalen, provided by the Paul B. Elder
Company, Bryan, Ohio). Patients were completely disrobed
and stood in the light box during UVA exposure. They wore
goggles during treatment and were instructed to wear sunglasses
for the remainder of the day. Treatments were administered
by trained technicians and ranged from less than 1min to more
than 1h.
The exposure (in joules/cm2) for the first treatment was
based on skin type, a graded estimate of sun tolerance and
facultative tanning determined from history and racial extraction
(Appendix 3). Since therapeutic results on the extremities lagged
behind those on the trunk, the protocol allowed for additional
exposure to the extremities, beginning with the first treatment
and increasing to 1\2 the total-body dose.
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